Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FIDIA'S HYALGAN PMA FOR OSTEOARTHRITIS PAIN RECOMMENDED FOR APPROVAL BY FDA ADVISORY PANEL; USE AFTER FAILED CONSERVATIVE THERAPY ENDORSED

This article was originally published in The Gray Sheet

Executive Summary

Fidia Pharmaceutical's Hyalgan premarket approval application received a unanimous recommendation for approval with conditions for treating pain caused by osteoarthritis of the knee from FDA's Orthopedic and Rehabilitation Devices Panel Nov. 21 in Gaithersburg, Maryland. The panel conditioned its approval recommendation on five labeling changes.

You may also be interested in...



Anika Revised PMA For Orthovisc Osteoarthritis Treatment Slated For July

Anika Therapeutics is pursuing a multiple-treatment indication for its Orthovisc sodium hyaluronic-acid (HA) injectable treatment for osteoarthritis of the knee, the firm reports.

US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived

Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel